Gilead Sciences (Australia)
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Gilead Sciences (Australia), Australia, covering academic research published from 2002 to 2024. Read More.
Open Access Percentage
71%
Total
Publications
84
Total Open
Publications
60
Total
Citations
4K
Open Access
Percentage
71%
Total
Publications
84
Total Open
Publications
60
Total
Citations
4K
Breakdown
Publisher Open
30%
Both
26%
Other Platform Open
15%
Closed
29%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 39%
18
Hybrid 22%
10
No Guarantees 39%
18
Other Platform Open
Domain 68%
23
Other Internet 29%
10
Institution 26%
9
Preprint 3%
1
Public 0%
0
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 23 |
DOI | Other Internet | 8 |
Unknown Repository | Other Internet | 2 |
Le Centre pour la Communication Scientifique Directe - HAL - Diderot | Institution | 2 |
Australian Defence Force Academy | Institution | 2 |
UNSW Sydney | Institution | 1 |
University of Modena and Reggio Emilia | Institution | 1 |
University of Melbourne | Institution | 1 |
University of Bristol | Institution | 1 |
University of Adelaide | Institution | 1 |